Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma
Launched by UNIVERSITY HOSPITAL MUENSTER · May 4, 2004
Trial Information
Current as of May 14, 2025
Unknown status
Keywords
ClinConnect Summary
OBJECTIVES: I. Determine whether morbidity can be reduced while preserving survival by substituting cyclophosphamide for ifosfamide in adjuvant combination chemotherapy in standard-risk patients with Ewing's sarcoma or peripheral neuroectodermal tumor (PNET). II. Determine whether survival is improved without unacceptable toxicity for high-risk patients with Ewing's sarcoma or PNET by the addition of etoposide to the VAIA regimen (vincristine/doxorubicin/ifosfamide/dactinomycin). III. Evaluate the impact of surgery and conventional vs. hyperfractionated radiotherapy (definitive and adjuvant...
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Biopsy-proven Ewing's sarcoma, atypical Ewing's sarcoma, and peripheral neuroectodermal tumors No soft tissue Ewing's sarcoma or other small cell sarcomas of soft tissue Such patients should be treated on the appropriate national Soft Tissue Sarcoma Protocol Treatment must begin within 3 weeks after diagnostic biopsy Registration must occur within 6 weeks after initiation of treatment
- • PATIENT CHARACTERISTICS: Age: Not over 35
- • PRIOR CONCURRENT THERAPY: No prior therapy, including primary definitive local therapy
About University Hospital Muenster
University Hospital Münster is a leading academic medical center in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and developing new therapeutic strategies. With a strong focus on collaboration and ethical research practices, University Hospital Münster plays a pivotal role in translating scientific discoveries into practical applications, fostering a culture of inquiry that benefits both the medical community and the patients it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newcastle Upon Tyne, England, United Kingdom
Patients applied
Trial Officials
Heribert F. Juergens, MD
Study Chair
University Hospital Muenster
Alan W. Craft, MD
Study Chair
Newcastle-upon-Tyne Hospitals NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials